Drug screening method and device based on blood-brain barrier injury model and medium

By using Evans blue staining and quantitative fluorescence technology, the problems of high cost, complex procedures, strong subjectivity and insufficient quantification in the existing blood-brain barrier assessment have been solved. This technology enables rapid and accurate assessment of blood-brain barrier leakage, improves the efficiency and accuracy of drug screening, and is applicable to various neurological disease models.

CN121354792APending Publication Date: 2026-01-16SHENZHEN LONGGANG DISTRICT OTOLARYNGOLOGY HOSPITAL (SHENZHEN OTOLARYNGOLOGY RES INST SHENZHEN LONGGANG DISTRICT ORAL MEDICINE RES INST)
0 Cites 0 Cited by

Patent Information

Application Number
CN202511418122.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-30
Publication Date
2026-01-16

AI Technical Summary

Technical Problem

Existing technologies for assessing blood-brain barrier leakage after radiation-induced brain injury suffer from problems such as in vivo/in vitro disconnect, high cost, complex procedures, strong subjectivity, and insufficient quantification, making it difficult to achieve large-scale drug screening and standardized evaluation.

Method used

Using Evans blue staining and quantitative fluorescence technology, experimental metadata and biological sample measurement data are collected and converted into absolute quantitative indicators of blood-brain barrier leakage, generating candidate drug efficacy predictions, simplifying the experimental process and supporting high-throughput screening.

Benefits of technology

It enables rapid and accurate assessment of blood-brain barrier leakage, lowers the research threshold, improves the efficiency and accuracy of drug screening, and is applicable to the development of blood-brain barrier protective drugs in various neurological disease models.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a drug screening method and device based on a blood-brain barrier injury model and a medium, and the method comprises the steps: collecting experimental metadata and biological sample measurement data of the blood-brain barrier injury model, the experimental metadata comprises an identifier of a candidate drug, an animal identifier, a body weight, an Evans blue injection volume, circulation time, perfusion time and a sampling position, and the biological sample measurement data comprises a brain tissue weight and a fluorescence intensity measurement value; converting the biological sample measurement data into a quantitative index of blood brain barrier leakage, wherein the quantitative index is the Evans blue leakage amount per gram of brain tissue; and generating a prediction effect of the candidate drugs according to experimental metadata and the quantitative indexes. The blood-brain barrier leakage can be rapidly and accurately evaluated through Evans blue staining and fluorescent quantitative technologies.
Need to check novelty before this filing date? Find Prior Art